Loren Jones, MD
Urology · Austin, TXNPI 1235392911
Payments from drug & device makers
Across 113 payments — averaging $484.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calyxo, Inc.$49K
- Boston Scientific$4K
- AbbVie$315
- Olympus America Inc.$292
- Johnson & Johnson$198
- Janssen Scientific Affairs, LLC$138
- plus $1K from 27 others
What the payments were for
- Speaking & faculty fees$3,69057%
- Food & beverage$2,76943%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calyxo, Inc. | 6 | $48,506 |
| Boston Scientific | 12 | $4,160 |
| AbbVie | 14 | $315 |
| Olympus America Inc. | 16 | $292 |
| Johnson & Johnson | 12 | $198 |
| Janssen Scientific Affairs, LLC | 1 | $138 |
| Merck | 5 | $125 |
| Pfizer | 7 | $113 |
| Ferring Pharmaceuticals Inc. | 4 | $100 |
| Dendreon Pharmaceuticals LLC | 3 | $98 |
| Bluewind Medical | 1 | $86 |
| Urogen Pharma, Inc. | 4 | $80 |
| Innovation Technologies Inc | 2 | $77 |
| Sumitomo Pharma America, Inc. | 3 | $61 |
| Procept Biorobotics Corporation | 1 | $43 |
| Endo Pharmaceuticals Inc. | 3 | $41 |
| Laborie Medical Technologies Corp. | 2 | $32 |
| Astellas Pharma US Inc | 2 | $31 |
| Urovant Sciences Inc | 1 | $30 |
| Bayer | 1 | $29 |
| AstraZeneca | 1 | $25 |
| Tolmar, Inc. | 1 | $22 |
| Telix Pharmaceuticals | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Novartis | 1 | $18 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Blue Earth Diagnostics | 1 | $17 |
| Immunitybio, Inc. | 1 | $16 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Civco Medical Instruments | 1 | $14 |
| Profound Medical Corp. | 1 | $12 |
| Valencia Technologies Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$3,690
- LithoVue$150
- LITHOCLAST$149
- Balversa$138
- Erleada$138
- CVAC$107
How this compares
$54,779 in reported general payments places this provider in the 85th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 129 | $1,810,517 |
| Abiraterone Acetate | 91 | $272,255 |
| OrgovyxRelugolix | 80 | $198,085 |
| NubeqaDarolutamide | 12 | $144,062 |
| MyrbetriqMirabegron | 40 | $42,556 |
| GemtesaVibegron | 31 | $28,634 |
| Silodosin | 69 | $6,021 |
| Mirabegron ErMirabegron | 12 | $5,959 |
| Tamsulosin Hcl | 389 | $5,504 |
| Potassium Citrate ErPotassium Citrate | 24 | $5,122 |
| Solifenacin Succinate | 138 | $4,716 |
| Testosterone Cypionate | 61 | $3,500 |
| Dutasteride | 64 | $2,041 |
| Finasteride | 130 | $1,556 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 92 | $1,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $198 | $1,810,517129 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $138 | $272,25591 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $61 | $226,719111 claims |
| BayerNubeqa | $29 | $144,06212 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $42,55640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 urology providers in Texas.
Other urology in Austin
- Michael TrotterAustin$892K
- Varun SundaramAustin$400K
- Elizabeth MobleyAustin$283K
- Parviz KavoussiAustin$251K
- Peter RuffAustin$168K
- Zvi SchiffmanHouston$17.8M
- Jose de la CerdaSan Antonio$9M
- Daniel SaltzsteinSan Antonio$5.8M
- Jose KaramHouston$5.7M
- Daniel ZainfeldSan Antonio$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.